ANT-FINANCIAL-SERVICES
27.5.2020 12:52:04 CEST | Business Wire | Press release
Ant Financial Services Group (“Ant Group”), an innovative technology provider, today announced a cooperative effort with Intel to make it much easier and cost-effective for SMEs to lease IT equipment, leveraging the application of blockchain technology to strengthen transparency and build a system of trust.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200527005464/en/
Using proprietary blockchain technology, the partnership aims to empower the IT equipment leasing industry while accelerating the digital transformation of SMEs, many of which have seen their capital flows and supply chains disrupted amid the COVID-19 pandemic.
This partnership draws from Ant Group and Intel’s complementary strengths to bolster transparency and efficacy among IT leasing vendors, enabling them to serve more SMEs and help them grow their businesses with improved efficiency and lowered cost.
Ant Blockchain, Ant Group’s proprietary productivity blockchain platform, can help all parties in the entire IT rental and leasing process to build trust with each other. Intel’s cloud device management technology helps leasing vendors to check the use status of the authorized hardware device using Intel’s CPU. Increasing the level of trust and transparency among all parties in the leasing process enables financial institutions, such as insurance companies and SME loan providers, to swiftly make informed decisions about businesses, giving SMEs greater flexibility to expand their operations.
“We are excited to partner with Intel as we continue to help millions of SMEs transform their businesses and operations,” said Geoff Jiang, Vice President of Ant Group. “Blockchain technology can play a pivotal role in building a solid system of trust among multiple parties and bringing more value to consumers, vendors, and the communities they operate in.”
Yali Liang, Vice President of Sales, Marketing and Communications Group of Intel, said, "With Ant Blockchain, we can help SMEs reduce fixed costs and alleviate pressure from IT equipment maintenance, which will accelerate the digital transformation of SMEs through IT rental industry."
Zugeliang, a Hangzhou-based IT equipment leasing platform, used Ant Blockchain to increase the level of trust among all parties involved in its leasing processes in 2019. Since then, the platform has seen a six-fold increase in the number of orders and a 200% improvement in the rate of timely payments.
About Ant Group
Ant Group is dedicated to using technology to bring the world equal opportunities. Our technologies, including blockchain, artificial intelligence, security, Internet of Things and computing empower us and our ecosystem partners to serve the unbanked and underbanked, bringing more secure, transparent, cost-effective and inclusive financial services to individuals and small and micro-sized businesses worldwide.
Ant Group has formed international partnerships with global strategic partners to serve local users in those markets, and we serve Chinese travelers overseas by connecting Alipay with online and offline merchants. Brands under Ant Group include Alipay, Ant Fortune, MYbank, and WorldFirst.
About Ant Blockchain
Ant Blockchain is the largest productivity blockchain platform in China with the ability to process and support one billion user accounts and one billion transactions every day. It has topped the global ranking for blockchain patent applications for the past three consecutive years.1
__________________
1
Based on research conducted by IPRDaily (2019
, 2018
, and 2017
, in Chinese).
View source version on businesswire.com: https://www.businesswire.com/news/home/20200527005464/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom